Towards immunotherapy for chronic hepatitis B virus infections.
Chronic liver disease and hepatocellular carcinoma associated with chronic hepatitis B virus (HBV) infection are among the most serious human health problems in highly endemic regions. Although, effective vaccines against HBV have been available for many years, over 350 million people still remain persistently infected with HBV. Current therapies fail to provide long-term control of viral replication in most patients. Viral persistence has been associated with a defect in the development of HBV-specific cell-mediated immunity. Vaccine-based strategies to boost or to broaden the weak virus-specific T cell response of patients with chronic hepatitis B are proposed as a means of terminating this persistent infection.
Michel
M-L
ML
Unité de Recombinaison et Expression Génétique, INSERM U. 163, Institut Pasteur, 28 rue du Docteur Roux, 75724 Paris Cédex 15, France. maloum@pasteur.fr
D006511:Hepatitis B Antigens / Q000276:immunology; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy
D006511:Hepatitis B Antigens; D017325:Hepatitis B Vaccines